Stock VCYT VERACYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Veracyte, Inc. Stock

Equities

VCYT

US92337F1075

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2025-01-23 pm EST 		5-day change 1st Jan Change
44.07 USD +2.37% Intraday chart for Veracyte, Inc. +7.23% +11.29%
Jan. 10 Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says MT
Dec. 05 Goldman Sachs Downgrades Veracyte to Neutral From Buy, Trims Price Target to $37 From $38 MT

Valuation: Veracyte, Inc.

Capitalization 3.42B 3.28B 3.1B 2.77B 4.91B 295B 5.44B 37.62B 13.83B 122B 12.81B 12.55B 533B P/E ratio 2024 *
132x
P/E ratio 2025 * 101x
Enterprise value 3.14B 3.02B 2.85B 2.55B 4.52B 272B 5B 34.62B 12.72B 112B 11.78B 11.54B 490B EV / Sales 2024 *
7.09x
EV / Sales 2025 * 6.29x
Free-Float
99.23%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Veracyte, Inc.

Dynamic Chart

Latest news: Veracyte, Inc.

Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says Jan. 10 MT
Goldman Sachs Downgrades Veracyte to Neutral From Buy, Trims Price Target to $37 From $38 Dec. 05 MT
Morgan Stanley Lifts Price Target on Veracyte to $28 From $26, Keeps Underweight Rating Nov. 18 MT
Wolfe Research Initiates Veracyte at Outperform With $50 Price Target Nov. 15 MT
Veracyte Insider Sold Shares Worth $585,663, According to a Recent SEC Filing Nov. 14 MT
Veracyte, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 11:45 AM Nov. 12
UBS Adjusts Price Target on Veracyte to $46 From $43, Maintains Buy Rating Nov. 07 MT
Earnings Flash (VCYT) VERACYTE Posts Q3 Revenue $115.9M Nov. 06 MT
Earnings Flash (VCYT) VERACYTE Reports Q3 EPS $0.33 Nov. 06 MT
Veracyte, Inc., Q3 2024 Earnings Call, Nov 06, 2024 Nov. 06
Veracyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 06 CI
Veracyte, Inc. Raises Earnings Guidance for the Full Year 2024 Nov. 06 CI
UBS Initiates Veracyte at Buy With $43 Price Target 24-10-16 MT
More news

Last Transcript: Veracyte, Inc.

Logo Veracyte, Inc.
Veracyte, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 11:45 AM
Nov. 12
More transcripts

Analysts' recommendations: Veracyte, Inc.

Goldman Sachs Downgrades Veracyte to Neutral From Buy, Trims Price Target to $37 From $38 Dec. 05 MT
Morgan Stanley Lifts Price Target on Veracyte to $28 From $26, Keeps Underweight Rating Nov. 18 MT
Wolfe Research Initiates Veracyte at Outperform With $50 Price Target Nov. 15 MT
UBS Adjusts Price Target on Veracyte to $46 From $43, Maintains Buy Rating Nov. 07 MT
UBS Initiates Veracyte at Buy With $43 Price Target 24-10-16 MT
More recommendations

Press Releases: Veracyte, Inc.

Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines Dec. 05 BU
Veracyte: Q3 Earnings Snapshot Nov. 06 AQ
Veracyte : Announces Third Quarter 2024 Financial Results Form 8 K Nov. 06 PU
Veracyte Announces Third Quarter 2024 Financial Results Nov. 06 BU
Veracyte to Participate in Upcoming Investor Conferences 24-10-30 BU
More press releases

News in other languages: Veracyte, Inc.

Veracyte : Prosigna Brustkrebs Gensignatur in Deutschland jetzt erstattet 21-07-06
Brussel in het rood 21-06-02
Ageas houdt Bel20 in bedwang 21-06-02
KBC Securities haalt Quest for Growth van kooplijst 21-06-02
Vlakke opening Brusselse beurs voorzien 21-06-02
More news

Quotes and Performance

1 day+2.37%
1 week+7.23%
Current month+11.29%
1 month+7.51%
3 months+35.81%
6 months+87.53%
Current year+11.29%
More quotes

Course Extremes

1 week
41.14
Extreme 41.135
44.42
1 month
38.89
Extreme 38.89
44.50
Current year
39.38
Extreme 39.38
44.50
1 year
18.61
Extreme 18.61
46.00
3 years
14.85
Extreme 14.85
46.00
5 years
13.90
Extreme 13.9
86.03
10 years
4.21
Extreme 4.21
86.03
More quotes

Managers and Directors: Veracyte, Inc.

Director TitleAgeSince
Marc Stapley CEO
 Chief Executive Officer 55 2021-05-31
Rebecca Chambers DFI
 Director of Finance/CFO 47 2021-07-18
Phillip Febbo CTO
 Chief Tech/Sci/R&D Officer 58 2023-10-01
Manager TitleAgeSince
Evan Jones BRD
 Director/Board Member 68 2008-01-31
Karin Eastham BRD
 Director/Board Member 75 2012-11-30
Robert Epstein CHM
 Chairman 59 -
More insiders

Bio Diagnostics & Testing

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
VERACYTE, INC. Stock Veracyte, Inc.
+2.37%+7.23%+66.49%+63.46%3.42B
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
+0.62%+9.30%-16.04%-25.53%10.2B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
+0.47%-3.09%-5.38%-56.94%2.01B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+3.34%+7.47%-20.44%-55.66%1.89B
CAREDX, INC Stock CareDx, Inc
+1.03%+6.21%+135.01%-36.73%1.26B
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
+1.50%+17.49%+86.04%-50.40%1.2B
SEEGENE, INC. Stock Seegene, Inc.
+1.04%-1.61%-2.98%-59.47%783M
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+5.83%+23.19%-10.63%-76.98%799M
VIMTA LABS LIMITED Stock Vimta Labs Limited
+3.41%+5.28%+105.91%+135.41%222M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
-1.39%-9.43%-0.78% - 215M
Average +1.84%+6.49%+33.72%-18.09% 2.2B
Weighted average by Cap. +1.40%+7.97%+13.63%-20.55%
See all sector performances

Financials

2024 *2025 *
Net sales 443M 426M 402M 359M 637M 38.31B 706M 4.88B 1.79B 15.8B 1.66B 1.63B 69.14B 487M 467M 442M 394M 699M 42.06B 775M 5.36B 1.97B 17.34B 1.82B 1.79B 75.89B
Net income 27.59M 26.5M 25.05M 22.36M 39.66M 2.38B 43.94M 304M 112M 983M 103M 101M 4.3B 36.67M 35.22M 33.3M 29.72M 52.72M 3.17B 58.41M 404M 149M 1.31B 138M 135M 5.72B
Net Debt -273M -262M -248M -221M -393M -23.6B -435M -3.01B -1.11B -9.73B -1.02B -1B -42.59B -356M -342M -323M -289M -512M -30.77B -567M -3.92B -1.44B -12.69B -1.33B -1.31B -55.53B
More financial data * Estimated data

Company Profile

Logo Veracyte, Inc.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Employees
815
Sector
Biotechnology & Medical Research
Calendar
2025-03-02 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
25-01-23 44.07 $ +2.37% 713,630
25-01-22 43.05 $ -1.26% 671,037
25-01-21 43.60 $ +7.44% 666,511
25-01-17 40.58 $ -1.27% 2,571,951
25-01-16 41.10 $ -1.49% 614,922

Delayed Quote Nasdaq, January 23, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart VERACYTE-INC More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
BBB
surperformance-ratings-light-chart VERACYTE-INCMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
44.07USD
Average target price
43.22USD
Spread / Average Target
-1.92%
Consensus
Profit revisions
estimates-change-chart VERACYTE-INC Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart VERACYTE-INC Company calendar
  1. Stock Market
  2. Equities
  3. VCYT Stock